On October 19, 2026, Integra LifeSciences Holdings Corporation announced the closing of a private unregistered offering of $450 million aggregate principal amount of 9.500% Senior Secured Notes due 2033. The Notes were offered only to qualified institutional buyers under Rule 144A of the Securities Act and to certain non-U.S. persons outside the United States in compliance with Regulation S.
In conjunction with the offering, the Company entered into an amended and restated credit agreement with a syndicate of lending banks, led by Bank of America, N.A., as Administrative Agent, Swing Line Lender, and L/C Issuer. The new Credit Agreement provides an aggregate principal amount of up to $1.65 billion, consisting of a $600 million senior secured revolving credit facility with a five-year maturity, a $600 million senior secured term loan A facility with a five-year maturity, and a $450 million senior secured term loan B facility with a seven-year maturity.
The Company utilized the net proceeds from the Notes offering, along with borrowings under the new Credit Agreement, to refinance its existing credit facility and pay related fees and expenses. The Company did not incur any early termination penalties in connection with the repayment of its previous Seventh Amended and Restated Credit Agreement.
The Notes bear interest at a rate of 9.500% per year, payable semi-annually in arrears on May 1 and November 1 of each year, commencing May 1, 2027. The Notes will mature on November 1, 2033, unless earlier repurchased or redeemed. The Company may redeem up to 40% of the aggregate principal amount of Notes prior to November 1, 2029, with the proceeds of certain equity offerings at a redemption price of 109.500% of their principal amount.
Under the terms of the Indenture governing the Notes, the Company is required to offer to purchase the Notes at a price equal to 101% of the principal amount in the event of a change of control. The Indenture also contains covenants that limit the Company’s ability to incur additional indebtedness, create liens, pay dividends, make capital stock redemptions, and engage in other restricted activities.
